CytoMed Therapeutics Limited (NASDAQ:GDTC) Sees Significant Increase in Short Interest

Posted by Caroline Horne on Jul 3rd, 2024

CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 38,800 shares, an increase of 9.9% from the May 31st total of 35,300 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average daily volume of 4,500 shares, the days-to-cover ratio is currently 8.6 days.

CytoMed Therapeutics Trading Up 0.5 %

Shares of GDTC stock traded up $0.01 during midday trading on Wednesday, hitting $2.04. The company had a trading volume of 2,235 shares, compared to its average volume of 20,058. The company has a current ratio of 14.09, a quick ratio of 14.09 and a debt-to-equity ratio of 0.04. The company’s 50 day simple moving average is $2.07 and its 200 day simple moving average is $2.65. CytoMed Therapeutics has a 52-week low of $1.89 and a 52-week high of $9.25.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $5.00 target price on shares of CytoMed Therapeutics in a report on Tuesday, June 11th.

Get Our Latest Research Report on GDTC

CytoMed Therapeutics Company Profile

(Get Free Report)

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.